Literature DB >> 10087083

Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes.

T P Wong1, T Debeir, K Duff, A C Cuello.   

Abstract

Cholinergic deficits are one of the most consistent neuropathological landmarks in Alzheimer's disease (AD). We have examined transgenic mouse models (PS1M146L, APPK670N,M671L) and a doubly transgenic line (APPK670N,M671L + PS1M146L) that overexpress mutated AD-related genes [presenilin-1 (PS1) and the amyloid precursor protein (APP)] to investigate the effect of AD-related gene overexpression and/or amyloidosis on cholinergic parameters. The size of the basal forebrain cholinergic neurons and the pattern of cholinergic synapses in the hippocampus and cerebral cortex were revealed by immunohistochemical staining for choline acetyltransferase and the vesicular acetylcholine transporter, respectively. At the time point studied (8 months), no apparent changes in either the size or density of cholinergic synapses were found in the PS1M146L mutant relative to the nontransgenic controls. However, the APPK670N,M671L mutant showed a significant elevation in the density of cholinergic synapses in the frontal and parietal cortices. Most importantly, the double mutant (APPK670N,M671L + PS1M146L), which had extensive amyloidosis, demonstrated a prominent diminution in the density of cholinergic synapses in the frontal cortex and a reduction in the size of these synapses in the frontal cortex and hippocampus. Nonetheless, no significant changes in the size of basal forebrain cholinergic neurons were observed in these three mutants. This study shows a novel role of APP and a synergistic effect of APP and PS1 that correlates with amyloid load on the reorganization of the cholinergic network in the cerebral cortex and hippocampus at the time point studied.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087083      PMCID: PMC6786057     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  53 in total

1.  Nerve growth factor and the monosialoganglioside GM1: analogous and different in vivo effects on biochemical, morphological, and behavioral parameters of adult cortically lesioned rats.

Authors:  L Garofalo; A C Cuello
Journal:  Exp Neurol       Date:  1994-02       Impact factor: 5.330

2.  Development and application of a monoclonal rat peroxidase antiperoxidase (PAP) immunocytochemical reagent.

Authors:  A C Cuello; C Milstein; B Wright; S Bramwell; J V Priestley; J Jarvis
Journal:  Histochemistry       Date:  1984

3.  Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.

Authors:  D R Borchelt; G Thinakaran; C B Eckman; M K Lee; F Davenport; T Ratovitsky; C M Prada; G Kim; S Seekins; D Yager; H H Slunt; R Wang; M Seeger; A I Levey; S E Gandy; N G Copeland; N A Jenkins; D L Price; S G Younkin; S S Sisodia
Journal:  Neuron       Date:  1996-11       Impact factor: 17.173

4.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

Authors:  N Suzuki; T T Cheung; X D Cai; A Odaka; L Otvos; C Eckman; T E Golde; S G Younkin
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

5.  Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal.

Authors:  E K Perry; J R Atack; R H Perry; J A Hardy; P R Dodd; J A Edwardson; G Blessed; B E Tomlinson; A F Fairbairn
Journal:  J Neurochem       Date:  1984-05       Impact factor: 5.372

6.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.

Authors:  M Citron; T Oltersdorf; C Haass; L McConlogue; A Y Hung; P Seubert; C Vigo-Pelfrey; I Lieberburg; D J Selkoe
Journal:  Nature       Date:  1992-12-17       Impact factor: 49.962

Review 7.  Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease.

Authors:  D J Selkoe
Journal:  Curr Opin Neurobiol       Date:  1994-10       Impact factor: 6.627

8.  Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles.

Authors:  M L Gilmor; N R Nash; A Roghani; R H Edwards; H Yi; S M Hersch; A I Levey
Journal:  J Neurosci       Date:  1996-04-01       Impact factor: 6.167

9.  Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease.

Authors:  E Masliah; A Sisk; M Mallory; L Mucke; D Schenk; D Games
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167

10.  Essential role of neocortical acetylcholine in spatial memory.

Authors:  J Winkler; S T Suhr; F H Gage; L J Thal; L J Fisher
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

View more
  36 in total

Review 1.  The role of presenilins in Alzheimer's disease.

Authors:  G Thinakaran
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Alzheimer's disease in man and transgenic mice: females at higher risk.

Authors:  R S Turner
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery.

Authors:  John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

4.  Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis.

Authors:  Karienn S Montgomery; George Edwards; Yona Levites; Ashok Kumar; Catherine E Myers; Mark A Gluck; Barry Setlow; Jennifer L Bizon
Journal:  Hippocampus       Date:  2015-10-19       Impact factor: 3.899

5.  Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.

Authors:  Jennifer Horgan; Jose Javier Miguel-Hidalgo; Martha Thrasher; Garth Bissette
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

6.  Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides.

Authors:  Gorazd B Stokin; Angels Almenar-Queralt; Shermali Gunawardena; Elizabeth M Rodrigues; Tomás Falzone; Jungsu Kim; Concepción Lillo; Stephanie L Mount; Elizabeth A Roberts; Eileen McGowan; David S Williams; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2008-08-11       Impact factor: 6.150

7.  Automated measurement of nerve fiber density using line intensity scan analysis.

Authors:  Aaron Sathyanesan; Tatsuya Ogura; Weihong Lin
Journal:  J Neurosci Methods       Date:  2012-02-28       Impact factor: 2.390

8.  Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP.

Authors:  M Dumont; R Lalonde; J-F Ghersi-Egea; K Fukuchi; C Strazielle
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

9.  Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain.

Authors:  Toshio Ariga; Makoto Yanagisawa; Chandramohan Wakade; Susumu Ando; Jerry J Buccafusco; Michael P McDonald; Robert K Yu
Journal:  ASN Neuro       Date:  2010-10-04       Impact factor: 4.146

10.  The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo.

Authors:  Juliet K Knowles; Jayakumar Rajadas; Thuy-Vi V Nguyen; Tao Yang; Melburne C LeMieux; Lilith Vander Griend; Chihiro Ishikawa; Stephen M Massa; Tony Wyss-Coray; Frank M Longo
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.